|

Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

RECRUITINGSponsored by Tianjin Medical University Second Hospital
Actively Recruiting
SponsorTianjin Medical University Second Hospital
Started2026-03
Est. completion2027-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07441499

Summary

Application of Multi-Component Liquid Biopsy (ctDNA, utDNA, Exosomes, and Protein Biomarkers in Blood and Urine) for Auxiliary Diagnosis, Therapeutic Response Evaluation, and Recurrence Monitoring in Urothelial Carcinoma

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Suspected or histologically confirmed urothelial carcinoma

Exclusion Criteria:

* History of or concurrent active malignancy other than urothelial carcinoma

Conditions4

Bladder (Urothelial, Transitional Cell) CancerCancerLiquid BiopsyUrothelial Carcinoma (UC)

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.